// App-Quantinova.ai

320 : Impact of Belatacept Conversion on Renal Function, Histology and Gene Expression in Kidney Transplant Patients with Chronic Active Antibody-Mediated Rejection

Researchers

Presenter

  • D. Kumar

Principal Investigators

  • M. Raynaud

  • P. Halloran

  • A. Loupy

  • J. Chang

  • J. Reeve

  • I. Yakubu

  • S. Bobba

  • L. Kamal

  • M. Levy

  • C. Bhati

  • P. Kimball

  • A. King

  • G. Gupta

Medical Centers

  • Virginia Commonwealth University, Mineral, VA

  • Paris Transplant Group, Paris, France

  • Alberta Transplant Genomics Applied Centre, Edmonton, AB, Canada

Locations

  • United States

  • France

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Chronic antibody mediated rejection

Biomarkers

  • N/A

Drug/Treatment

  • Belatacept

  • Tacrolimus

  • Rituximab

  • IVIG

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved